OncoGenex Pharma (OGXI) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014
March 26, 2015 4:01 PM EDTConference call to be held on Thursday, March 26, 2015 at 4:30 p.m. Eastern Time
BOTHELL, Wash. and VANCOUVER, British Columbia, March 26, 2015 /PRNewswire/ --Â OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced fourth quarter and year end 2014 financial results.
Clinical Developments and Anticipated Near-term Milestones
Custirsen
Collaboration: In December 2014, OncoGenex and Teva agreed to negotiate the termination of their collaboration and return custirsen rights to OncoGenex. Negotiations of the final termination agreement are ongoing. Two Phase 3 Trials: OncoGenex' custirsen... More